期刊
VIRUSES-BASEL
卷 13, 期 4, 页码 -出版社
MDPI
DOI: 10.3390/v13040628
关键词
SARS-CoV-2; COVID-19; neutralizing antibody; resistance; casirivimab; imdevimab; bamlanivimab; etesevimab
类别
资金
- F. Hoffmann-La Roche Ltd.
The emergence of SARS-CoV-2 and the subsequent COVID-19 pandemic have created an urgent need for effective therapeutic strategies. Neutralizing antibodies have shown potential in treating and preventing COVID-19, but their efficacy in severe cases remains varied. Treatment may lead to the formation of antiviral resistant escape mutants, highlighting the importance of exploring strategies to minimize risk.
The emergence of SARS-CoV-2 and subsequent COVID-19 pandemic has resulted in a significant global public health burden, leading to an urgent need for effective therapeutic strategies. In this article, we review the role of SARS-CoV-2 neutralizing antibodies (nAbs) in the clinical management of COVID-19 and provide an overview of recent randomized controlled trial data evaluating nAbs in the ambulatory, hospitalized and prophylaxis settings. Two nAb cocktails (casirivimab/imdevimab and bamlanivimab/etesevimab) and one nAb monotherapy (bamlanivimab) have been granted Emergency Use Authorization by the US Food and Drug Administration for the treatment of ambulatory patients who have a high risk of progressing to severe disease, and the European Medicines Agency has similarly recommended both cocktails and bamlanivimab monotherapy for use in COVID-19 patients who do not require supplemental oxygen and who are at high risk of progressing to severe COVID-19. Efficacy of nAbs in hospitalized patients with COVID-19 has been varied, potentially highlighting the challenges of antiviral treatment in patients who have already progressed to severe disease. However, early data suggest a promising prophylactic role for nAbs in providing effective COVID-19 protection. We also review the risk of treatment-emergent antiviral resistant escape mutants and strategies to minimize their occurrence, discuss the susceptibility of newly emerging SARS-COV-2 variants to nAbs, as well as explore administration challenges and ways to improve patient access.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据